- $932.79m
- $789.86m
Savara Q2 loss widens as operating expenses rise
Brief: Savara Q2 Net Income USD -40.228 Million
Brief: Savara Announces Chief Financial And Administrative Officer Transition
Savara Q1 net loss widens on higher R&D costs
Brief: Savara Q1 Net Income USD -37.284 Million
Brief: Savara Announces The U.S. Food & Drug Administration (FDA) Has Extended The Review Period For The Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
Savara rises as UK accepts application for rare lung disease drug
Brief: Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
Savara Q4 net loss widens as expenses rise
Brief: Savara Q4 Net Income USD -32.236 Million
Brief: Savara Provides Regulatory Update On The MOLBREEVI* Development Program In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
Brief: Savara Resubmits The Biologics License Application To The U.S. Food And Drug Administration For Molbreevi
Savara Q3 net loss widens
Brief: Savara Q3 Net Income USD -29.561 Million
U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna
Biotech co Savara falls after $130 mln equity offering